Metabolic syndrome: adenosine monophosphate-activated protein kinase and malonyl coenzyme A.
The metabolic syndrome can be defined as a state of metabolic dysregulation characterized by insulin resistance, central obesity, and a predisposition to type 2 diabetes, dyslipidemia, premature atherosclerosis, and other diseases. An increasing body of evidence has linked the metabolic syndrome to abnormalities in lipid metabolism that ultimately lead to cellular dysfunction. We review here the hypothesis that, in many instances, the cause of these lipid abnormalities could be a dysregulation of the adenosine monophosphate-activated protein kinase (AMPK)/malonyl coenzyme A (CoA) fuel-sensing and signaling mechanism. Such dysregulation could be reflected by isolated increases in malonyl CoA or by concurrent changes in malonyl CoA and AMPK, both of which would alter intracellular fatty acid partitioning. The possibility is also raised that pharmacological agents and other factors that activate AMPK and/or decrease malonyl CoA could be therapeutic targets.
T10 T11 T12 T13 T1 T2 T3 T4 T5 T6 T7 T8 T9
GENE-N GENE-N GENE-Y GENE-N CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL GENE-N GENE-N
AMPK AMPK insulin adenosine monophosphate-activated protein kinase adenosine monophosphate malonyl coenzyme A malonyl CoA malonyl CoA malonyl CoA adenosine monophosphate malonyl coenzyme A adenosine monophosphate-activated protein kinase AMPK